## Biostatistical Methods I (BIOS 5710) Breheny

Assignment 12: Solutions

1. (a)

| Therapy | Time | Death/Transplant | $n(t)$ | $\hat{S}(T)$ |
| :--- | ---: | :---: | :---: | :---: |
|  | $\ldots$ |  |  |  |
| Penicillamine | 799 | Yes | 139 | .873 |
| Penicillamine | 824 | Yes | 138 | .867 |
| Penicillamine | 839 | No | 137 | .867 |
| Penicillamine | 877 | Yes | 136 | .860 |
| Penicillamine | 901 | Yes | 135 | .854 |
| Penicillamine | 904 | Yes | 134 | .848 |
|  | $\ldots$ |  |  |  |

(b)

|  | Death/Transplant |  |
| :--- | :---: | :---: |
|  | Yes | No |
| Penicillamine | 0 | 136 |
| Placebo | 1 | 127 |

(c) Answers for (i) and (ii) can be obtained via:

Data <- read.delim("http://myweb.uiowa.edu/pbreheny/data/cirrhosis.txt")
require(survival)
S <- with (Data, Surv(Time,Status!=0))
Group <- Data\$Group
survdiff (S~Group)
fit <- survfit (S~Group)
plot(fit,mark.time=FALSE, col=c("red","gray"), lwd=3, xlab="Years", ylab="Progression-free Survival")
legend("bottomleft",levels(Group), lwd=3, col=c("red","gray"))
(i) The Log-Rank test yields $p=0.73$.
(ii)

(iii) Yes, both the analysis above and the literature review indicate that there is no difference in survival for patients on penicillamine and those on placebo.
(d) (i) Approximately $65 \%$ for both.
(ii) About 7 years for the penicillamine group and 8.5 years for the placebo group.
(e) (i) wider, because more subjects have been censored by 9 years as compared to 1 year.
(f) (iii) narrower, because fewer patients will have been censored before the 25 th percentile than the 50th percentile (the median).

